Lupin’s wholly owned subsidiary -- Lupin Manufacturing Solutions (LMS) has commissioned dedicated Oncology Block at Vizag facility in India. The new high-containment unit significantly enhances LMS’s end-to-end contract development and manufacturing capabilities for High Potent Active Pharmaceutical Ingredients. It will support clients across the oncology development lifecycle from preclinical research to commercial manufacturing, addressing growing global demand for oncology drug development and manufacturing.

Spanning 4,270 square meters, the new facility, is equipped with 20 reactors, ranging from 250L to 2000L, with over 20 isolators and advanced containment systems. Designed with flexible scale-up capabilities (1-35 kg batch range) and comprehensive environmental controls (≤25 degree Celsius, ≤45% RH), the facility allows for safe, efficient, and compliant production of oncology APIs that meet global quality standards.

The new facility integrates the Process Development Laboratory with a dedicated Quality Control laboratory, enabling early-stage route scouting, analytical development, process optimization, and validation - all in one location. 

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.